The venture, Onduo, plans to combine devices, software and medicine, according to a statement yesterday from Sanofi and Verily, previously known as Google Life Sciences. It plans to distinguish itself from rivals with programs like the Verily venture, unveiled last year, Oelrich said. The company plans to step up efforts to convince purchasers that its drugs are better than rivals’ treatments, Oelrich said. Sanofi is carrying out “the biggest real-world evidence” program ever for Toujeo to highlight to payers the differences between the treatments, Oelrich said. The Sanofi and Verily venture will focus on developing ways to improve medication management and habits for patients and will be led by Joshua Riff as chief executive officer.

Source: Taipei Times September 12, 2016 16:04 UTC